Global Pulmonary Arterial Hypertension (PAH) Market: Snapshot
Pulmonary arterial hypertension (PAH) is a very rare type of progressive disorder related to high blood pressure. However, the rate of incidence of this disorder is gradually gaining traction. Various sources, including WHO and CDC, suggest that the global prevalence of PAH is anticipated to be between 100,000 and 200,000, narrowing down to about 15-50 cases per million heads. There is no permanent cure for PAH available in the market, which renders the market highly opportunistic. According to a report by Transparency Market Research (TMR), the global PAH market is estimated to reach a valuation of US$5.19 bn by the end of 2020, expanding at a tremendous CAGR of 17.90% between 2014 and 2020.
Several treatments are available to control symptoms, slow down the progression of the disease, and enhance the quality of life. The approval of some effective drugs in recent times and the presence of a promising pipeline are among the primary factors providing a significant boost to the global pulmonary arterial hypertension market. Favorable government initiatives are also playing a vital role in the development of the market.
A TMR analyst states that however, the patent expiry of some of the blockbuster drugs are paving way for penetration of generic drugs. Generic drugs are usually 70% to 80% cheaper than branded drugs and therefore, their increased sales adversely affect the overall revenue generation of the market. On the other hand, the future of the global market looks bright with the development of cutting-edge therapies for the treatment of PAH.
Prostacyclin and Prostacyclin Analogs to Rise to Forefront during Forecast Period
On the basis of drug class, the report segments the global PAH market into PDE-5 inhibitors, endothelin receptor antagonists (ERAs), prostacyclin and prostacyclin analogs, and soluble guanylate cyclase (sGC) stimulators and selexipag. The ERAs segment dominated the market in terms of value at the beginning of the forecast period. However, by the end of this period, the prostacyclin and prostacyclin analogs segment will surpass ERAs. The growth of the segment can be mainly attributed to the approval of new drugs such as Uptravi (selexipag) in December 2015 and Orenitram (treprostinil) in December 2013. While in the case of sGC stimulator, Adempas (riociguat) is the only approved drug for the treatment of PAH.
Availability of Newly-approved PAH Drugs to Fuel Dominance of North America
North America will continue to account for the lion’s share until 2020, closely trailed by Europe. These two developed regions will exhibit remarkable growth during the forecast period, thanks to the availability of newly-approved PAH drugs along with the presence of a promising pipeline. The high awareness among the populace regarding the availability of treatment for pulmonary arterial hypertension is also driving the growth of the regions.
The Asia Pacific market will also be highly opportunistic in nature. Countries such as Japan, Australia, India, New Zealand, and China will be sights of high growth rates in the region and therefore, will be emerging destinations for global players. Rest of the World, on the other hand, is likely to register sluggish growth during the same period. The lack of awareness related to the detection and treatment of PAH is acting as a bottleneck in the development of the region.
Some of the prominent participants in the global pulmonary arterial hypertension market are Gilead Sciences Inc., Actelion Pharmaceuticals Ltd., GlaxoSmithKline Plc., Bayer HealthCare, Novartis International AG, Pfizer Inc., and United Therapeutics Corp.
- Prostacyclin and Prostacyclin Analogs
- Endothelin Receptor Antagonists (ERAs)
- Phosphodiesterase-5 (PDE-5) Inhibitors
- Soluble Guanylate Cyclase (sGC) Stimulators
- Early-stage Drug Candidates (Phase I & Phase II)
- Late-stage Drug Candidates (Phase III & Registration Phase)
- North America
- Rest of the World (RoW)